OpGen Inc (NASDAQ:OPGN) has been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Analysts have set a one year consensus target price of $30.00 for the company, according to Zacks. Zacks has also assigned OpGen an industry rank of 114 out of 255 based on the ratings given to related companies.
Separately, Zacks Investment Research cut OpGen from a “buy” rating to a “hold” rating in a research note on Wednesday, February 5th.
OPGN traded down $0.04 during midday trading on Friday, hitting $1.63. 202,968 shares of the company were exchanged. OpGen has a 1-year low of $0.92 and a 1-year high of $31.80. The firm’s 50 day moving average price is $1.56 and its 200-day moving average price is $2.75.
OpGen Company Profile
OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.
Recommended Story: What Are Cryptocurrencies?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.